This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wu, S. Articles by Seeger, K. Search for Related Content PubMed PubMed Citation Articles by Wu, S. Articles by Seeger, K. Social Bookmarking                            What's this?

Expression of Interleukin-10 Splicing Variants Is a Positive Prognostic Feature in Relapsed Childhood Acute Lymphoblastic Leukemia

From the Department of Pediatric Oncology/Hematology, and Institute of Laboratory Medicine and Biochemistry, Charité Medical Center, Humboldt University at Berlin, Berlin, Germany

Address reprint requests to Shuling Wu, MD, Institute of Laboratory Medicine and Pathobiochemistry, Charité Medical Center, Humboldt University Berlin, Augustenburger Platz 1, 13353 Berlin, Germany; e-mail: shuling.wu{at}charite.de

PURPOSE: Biologic features of hematologic malignancies have prognostic implications and are essential elements in the design of current therapeutic trials. This study aimed to determine the expression of a splicing-derived variant of interleukin (IL) -10 in leukemic cells and its clinical relevance in children with acute lymphoblastic leukemia (ALL) at first relapse.

PATIENTS AND METHODS: Between January 1997 and December 2001, bone marrow (BM) samples were collected from 98 children with first relapse of ALL at diagnosis. These patients were enrolled in the relapse trial ALL-REZ BFM (ALL-Relapse Berlin-Frankfurt-Münster) 95 and 96. The detection of IL-10 isoforms in leukemic cells of BM samples were performed by conventional reverse transcriptase polymerase chain reaction and by immunoblotting.

RESULTS: IL-10 was detected in 93.9% BM samples. In addition to expressing full-length IL-10, a new splicing-derived IL-10 variant (termed IL-103) that lacked the entire exon 3 was identified in leukemic cells. The IL-103 variant was found in 80.4% of BM samples. Most importantly, expression of IL-103 was associated with a significantly better response to chemotherapy (P = .001) and probability of event-free survival (P = .01) at 5 years.

CONCLUSION: These results indicate that splicing-derived IL-10 isoforms may modulate IL-10–mediated biologic effects and therapeutic efficacy in lymphatic disease, and expression of IL-103 is a positive prognostic feature in relapsed childhood ALL.

Supported by a grant from the Deutsche Krebshilfe, Bonn, Germany, and by KINDerLEBEN, Kinderkrebsforschungszentrum Berlin, Germany.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. W. Hsing, L. C. Sakoda, A. Rashid, G. Andreotti, J. Chen, B.-S. Wang, M.-C. Shen, B. E. Chen, P. S. Rosenberg, M. Zhang, et al. Variants in Inflammation Genes and the Risk of Biliary Tract Cancers and Stones: A Population-Based Study in China Cancer Res., August 1, 2008; 68(15): 6442 - 6452. [Abstract] [Full Text] [PDF]

				H. H. Park, M. Kim, B.-H. Lee, J. Lim, Y. Kim, E. J. Lee, W. S. Min, C. S. Kang, W. I. Kim, S. I. Shim, et al. Intracellular IL-4, IL-10, and IFN-{gamma} Levels of Leukemic Cells and Bone Marrow T Cells in Acute Leukemia. Ann. Clin. Lab. Sci., December 1, 2006; 36(1): 7 - 15. [Abstract] [Full Text] [PDF]

				L. W. Harries, S. Ellard, A. Stride, The European MODY consortium, N. G. Morgan, and A. T. Hattersley Isomers of the TCF1 gene encoding hepatocyte nuclear factor-1 alpha show differential expression in the pancreas and define the relationship between mutation position and clinical phenotype in monogenic diabetes Hum. Mol. Genet., July 15, 2006; 15(14): 2216 - 2224. [Abstract] [Full Text] [PDF]